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in mild hyperlipidaemic individuals
M. Jan, P.S. Thondre, A. El-Chab and H.J. Lightowler
Functional Food Centre, Oxford Brookes University, Oxford OX3 0BP, UK
Hyperlipidaemia is a risk factor for cardiovascular disease and, according to the British Heart Foundation (2015), over half of
England’s adult population suffers from high cholesterol levels(1). Phosphatidylcholine (PC) is a class of lipids mainly found in egg
yolk and soy bean. Several studies have suggested that PC supplementation can help in improving blood lipid proﬁle(2–3). The aim
of the present study was to investigate the effect of two different doses of PC supplementation (600 mg and 2400 mg) on blood
lipid proﬁle in individuals with mild elevated levels of low-density lipoprotein cholesterol (LDL-C).
In a parallel intervention study, ten participants (mean age 44 ± 13 years) were randomly allocated to either a low dose (600 mg;
LDG) or high dose (2400 mg; HDG) PC supplement group for 4 weeks. A capillary blood sample was taken at baseline, after two
weeks and four weeks of PC supplementation. Measurement of total cholesterol (TC), LDL-C, high-density lipoprotein cholesterol
(HDL-C), non-HDL-C, TC/HDL-C ratio and triglycerides (TG) was analysed using the CardioChek Professional Analyser.
At baseline, the mean blood lipid concentrations were similar in both groups. After four weeks of treatment, there was a signiﬁcant
(P < 0·05) reduction in TC in the HDG compared to the LDG. Levels of LDL-C, non-HDL-C and TC/HDL ratio show a slight
decrease at week 4 in both groups (Table 1).
The results from the current study indicate that 2400 mg of PC supplementation can signiﬁcantly decrease TC levels and may help
reduce LDL-C levels. LDL-C is considered to be a primary indicator for developing CVD. Although many hypolipidaemic drugs are
available for patients, these may not fully achieve the required levels of lipids and may cause adverse effects such as increasing the risk
of developing diabetes mellitus. Further research in this area is required to conﬁrm the effect of PC supplementation on lipid proﬁle in
patients at risk of developing CVD.
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Table 1. Comparison of the change in blood lipid proﬁle from baseline between
the two groups
Variables LDG n= 6 HDG n= 4 P Value
Total cholesterol (mmol/l)
2weeks −0·2 ± 0·7 −0·5 ± 0·8 0·476
4 weeks 0·0 ± 0·3 −0·5 ± 0·4 0·035
TGs (mmol/l)
2 weeks 0·2 ± 0·3 −0·0 ± 0·8 0·476
4 weeks 0·3 ± 0·7 −0·6 ± 0·8 0·171
HDL-C (mmol/l)
2 weeks 0·1 ± 0·4 −0·0 ± 0·1 0·499
4 weeks 0·2 ± 0·3 −0·1 ± 0·2 0·110
LDL-C (mmol/l)
2weeks −0·4 ± 0·3 −0·5 ± 0·7 0·803
4weeks −0·3 ± 0·5 −0·2 ± 0·7 0·706
Non-HDL-C (mmol/l)
2 weeks −0·3 ± 0·3 −0·5 ± 0·9 0·684
4 weeks −0·2 ± 0·3 −0·4 ± 0·4 0·323
TC/HDL ratio (mmol/l)
2 weeks −0·3 ± 0·3 −0·4 ± 0·9 0·934
4 weeks −0·3 ± 0·4 −0·3 ± 0·7 0·850
(Independent-sample t-test and the Mann-Whitney test; signiﬁcance difference
P < 0·05)
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